Suppr超能文献

新冠病毒抗体在新冠确诊后的存在情况:纽约一家主要紧急护理提供商的患者的纵向研究。

Presence of SARS-CoV-2 antibodies following COVID-19 diagnosis: a longitudinal study of patients at a major urgent care provider in New York.

机构信息

Institute for Implementation Science in Population Health, City University of New York. New York, NY USA.

Institute for Implementation Science in Population Health, City University of New York. New York, NY USA.

出版信息

Diagn Microbiol Infect Dis. 2022 Aug;103(4):115720. doi: 10.1016/j.diagmicrobio.2022.115720. Epub 2022 May 4.

Abstract

The duration of antibody persistence following natural infection is unclear. We examined routine SARS-CoV-2 diagnostic and serological testing data on 6522 persons diagnosed between March 2020 and March 2021 who had at least 1 antibody test ≥30 days after diagnosis at CityMD, an urgent care provider. Using survival analysis, we estimated the median duration of detectable anti-SARS-CoV-2 antibodies and hazard of seroreversion by demographic and clinical characteristics. We found that over 90% (95% CI: 91.8%, 94.8%) of the study population had detectable levels of antibodies at 180 days post diagnosis and that SARS-CoV-2 antibodies persisted at a detectable level for a median duration of 342 days following infection (95% CI: 328, 361). Additionally, there were differences in antibody persistence by age, with older patients less likely to serorevert compared to younger patients. These findings suggest that protection from natural infection may wane with time and differ by demographic factors.

摘要

自然感染后抗体持续时间尚不清楚。我们对 2020 年 3 月至 2021 年 3 月期间在 CityMD(一家急诊护理提供者)就诊且至少有 1 次抗体检测在诊断后≥30 天的 6522 名确诊患者的常规 SARS-CoV-2 诊断和血清学检测数据进行了检查。使用生存分析,我们根据人口统计学和临床特征估计了抗 SARS-CoV-2 抗体的中位持续检测时间和血清学转换的风险。我们发现,超过 90%(95%CI:91.8%,94.8%)的研究人群在诊断后 180 天具有可检测水平的抗体,并且 SARS-CoV-2 抗体在感染后中位持续 342 天(95%CI:328,361)仍可检测。此外,抗体的持续时间存在年龄差异,与年轻患者相比,老年患者血清学转换的可能性较小。这些发现表明,自然感染的保护作用可能会随着时间的推移而减弱,并且存在人口统计学因素的差异。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aae3/9065597/0b49bb080551/gr1_lrg.jpg

相似文献

1
Presence of SARS-CoV-2 antibodies following COVID-19 diagnosis: a longitudinal study of patients at a major urgent care provider in New York.
Diagn Microbiol Infect Dis. 2022 Aug;103(4):115720. doi: 10.1016/j.diagmicrobio.2022.115720. Epub 2022 May 4.
2
SARS-CoV-2 pandemic in New York metropolitan area: the view from a major urgent care provider.
Ann Epidemiol. 2022 Oct;74:31-40. doi: 10.1016/j.annepidem.2022.05.006. Epub 2022 Jun 2.
4
The influence of time on the sensitivity of SARS-CoV-2 serological testing.
Sci Rep. 2022 Jun 22;12(1):10517. doi: 10.1038/s41598-022-14351-2.
7
Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
Microbiol Spectr. 2021 Oct 31;9(2):e0059021. doi: 10.1128/Spectrum.00590-21. Epub 2021 Sep 22.
8
Longitudinal assessment of anti-SARS-CoV-2 antibody dynamics and clinical features following convalescence from a COVID-19 infection.
Int J Infect Dis. 2021 Jun;107:221-227. doi: 10.1016/j.ijid.2021.04.080. Epub 2021 Apr 28.

引用本文的文献

1
COVID-19 Seroprevalence in Romania: Insights from a Nationwide Antibody Study.
Epidemiologia (Basel). 2025 Jun 4;6(2):26. doi: 10.3390/epidemiologia6020026.
2
Seroprevalence and risk factors for SARS-CoV-2 infection in middle-sized cities of Burkina Faso: A descriptive cross-sectional study.
PLoS One. 2024 Aug 7;19(8):e0305850. doi: 10.1371/journal.pone.0305850. eCollection 2024.

本文引用的文献

2
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.
N Engl J Med. 2021 Aug 12;385(7):585-594. doi: 10.1056/NEJMoa2108891. Epub 2021 Jul 21.
4
SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy.
EClinicalMedicine. 2021 May;35:100861. doi: 10.1016/j.eclinm.2021.100861. Epub 2021 Apr 28.
5
Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination.
Clin Infect Dis. 2021 Dec 6;73(11):2065-2072. doi: 10.1093/cid/ciab381.
6
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19.
N Engl J Med. 2021 Jun 10;384(23):2259-2261. doi: 10.1056/NEJMc2103916. Epub 2021 Apr 6.
7
Prolonged viral shedding and antibody persistence in patients with COVID-19.
Microbes Infect. 2021 May-Jun;23(4-5):104810. doi: 10.1016/j.micinf.2021.104810. Epub 2021 Mar 17.
9
The dichotomous and incomplete adaptive immunity in COVID-19 patients with different disease severity.
Signal Transduct Target Ther. 2021 Mar 8;6(1):113. doi: 10.1038/s41392-021-00525-3.
10
Adaptive immunity to SARS-CoV-2 and COVID-19.
Cell. 2021 Feb 18;184(4):861-880. doi: 10.1016/j.cell.2021.01.007. Epub 2021 Jan 12.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验